Advertisement

Topics

Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adult (18-40 Years Old)

2014-08-27 03:13:40 | BioPortfolio

Summary

This trial is aimed to evaluate the safety and immunogenicity profiles of a new Vi-CRM197 conjugate vaccine against S. Typhi in healthy human adults in comparison with the currently licensed Vi polysaccharide vaccine.

Study Design

Allocation: Randomized, Control: Active Control, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention

Conditions

Typhoid Fever

Intervention

Vi-CRM197 glycoconjugated vaccine

Location

Center for the Evaluation of Vaccination, Vaxinfectio - Vaccine & Infectious Disease Institute, Universiteit Antwerpen - Univers
Campus Drie Eiken, Universiteitsplein 1
Wilrijk (Antwerpe)
Belgium
2610

Status

Active, not recruiting

Source

Novartis

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:13:40-0400

Clinical Trials [2240 Associated Clinical Trials listed on BioPortfolio]

Introduction of the Vi Polysaccharide Typhoid Vaccine in Hue City, Central Vietnam

This study is part of International Vaccine Institutes (IVI)'s typhoid Vi demonstration project that aims to accelerate the rational introduction of Vi vaccines in typhoid endemic countrie...

Global Genomic and Proteomic Profiling of African Children With Typhoid Fever

To develop a rapid, sensitive, and inexpensive diagnostic method, as well as more efficacious vaccine, for countries where typhoid fever remains a major public health burden.

Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever

This study is part of the International Vaccine Institute's (IVI's) typhoid Vi demonstration project that aims to accelerate the rational introduction of Vi vaccines in typhoid endemic cou...

Typhoid Conjugate Vaccine Introduction in Navi Mumbai, India

The purpose of this study is to evaluate the impact of a government-led typhoid conjugate vaccine introduction program on typhoid disease burden in Navi Mumbai, India.

Combined Vi Vaccination and Health Education Program on the Burden of Typhoid in Childhood

This study is part of the International Vaccine Institute's (IVI's) typhoid Vi demonstration project that aims to accelerate the rational introduction of Vi vaccines in typhoid endemic cou...

PubMed Articles [2143 Associated PubMed Articles listed on BioPortfolio]

Activation of coagulation and endothelium with concurrent impairment of anticoagulant mechanisms in patients with typhoid fever.

Typhoid fever caused by Salmonella Typhi remains a major burden worldwide. Gastrointestinal bleeding can be seen in up to 10 percent of patients and may be fatal. The coagulopathy, which may be the dr...

Epidemiology and risk factors for typhoid fever in Central Division, Fiji, 2014-2017: A case-control study.

Typhoid fever is endemic in Fiji, with high reported annual incidence. We sought to identify the sources and modes of transmission of typhoid fever in Fiji with the aim to inform disease control.

What is the best immunization strategy for protecting African children against invasive Salmonella disease?

The WHO recently prequalified a typhoid conjugate vaccine (TCV), recommending its use in persons aged ≥6 months to 45 years residing in typhoid fever (TF)-endemic areas. We now need to consider how ...

Massive Lower Gastrointestinal Bleed caused by Typhoid Ulcer: Conservative Management.

Typhoid fever is caused by gram-negative organism Salmonella typhi. The usual presentation is high-grade fever, but complications like gastrointestinal (GI) hemorrhage and perforation are also seen fr...

Open label comparative trial of mono versus dual antibiotic therapy for Typhoid Fever in adults.

Emerging resistance to antibiotics renders therapy of Typhoid Fever (TF) increasingly challenging. The current single-drug regimens exhibit prolonged fever clearance time (FCT), imposing a great burde...

Medical and Biotech [MESH] Definitions

Vaccines used to prevent TYPHOID FEVER and/or PARATYPHOID FEVER which are caused by various species of SALMONELLA. Attenuated, subunit, and inactivated forms of the vaccines exist.

Vaccine used to prevent YELLOW FEVER. It consists of a live attenuated 17D strain of the YELLOW FEVER VIRUS.

Vaccines or candidate vaccines used to prevent infection with SALMONELLA. This includes vaccines used to prevent TYPHOID FEVER or PARATYPHOID FEVER; (TYPHOID-PARATYPHOID VACCINES), and vaccines used to prevent nontyphoid salmonellosis.

A prolonged febrile illness commonly caused by several Paratyphi serotypes of SALMONELLA ENTERICA. It is similar to TYPHOID FEVER but less severe.

A serotype of SALMONELLA ENTERICA which is the etiologic agent of TYPHOID FEVER.

More From BioPortfolio on "Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adult (18-40 Years Old)"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Vaccine
A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one ...


Searches Linking to this Trial